Monday, August 13, 2012

A Plavix a Day Keeps MI Away?

Motivation: Last week, I was trying to coax a patient into taking aspirin every day, and he refused to give way.  He had stomach pain after every dose of aspirin.  To me, it seemed reasonable to refuse aspirin, but then again, I did not want his next stroke on my conscience either.  I wondered if there was a way out or even a better way.  How good is clopidogrel compared to aspirin for prevention of vascular events in high risk populations?

Paper: CAPRIE Steering Committee, "A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)" Lancet (1996); 348: 1329-39.

Methods: Randomised blinded trial of 19,185 adults in USA, Canada, and Europe with symptomatic atherosclerotic peripheral arterial disease, recent MI (within 5 weeks), or recent ischemic stroke (within 6 months).  Patients with bleeding disorders were excluded.  Patients were randomized to clopidogrel 75 mg daily or aspirin 325 mg daily.  Primary outcome was ischemic stroke, MI, or vascular death.  Secondary outcomes included all-cause mortality, intracranial hemorrhage, fatal bleeds, and other clusters of outcomes.  Mean duration of follow-up was 1.91 years.

Results: 
Cohort: Among 19,185 patients, 9,586 were randomized to aspirin while 9,599 were randomized to clopidogrel.  Mean age of cohort was 62.5 years, and the cohort was 72% male and 95% white.  Baseline characteristics of the patients in terms of comorbidities were evenly balanced.  Prior to end of study, 21.3% in clopidogrel group and 21.1% in aspirin group discontinued drug.  Most common cause for stopping was adverse drug effect.

Primary Outcome: For the primary outcome of ischemic stroke, MI, or vascular death, the average event rate per patient year was 5.32% in clopidogrel group and 5.83% in aspirin, yielding a relative risk reduction of 8.7% (95% CI 0.3-16.5%, p = 0.043), in favor of clopidogrel.

Secondary Outcome: For the pre-defined secondary outcome measures of vascular death, death from any cause, or cluster of ischemic/hemorrhagic stroke, MI, and death, there was no difference between aspirin and clopidogrel.

Post-Hoc Analysis: In post-hoc subgroup analysis, patients with peripheral arterial disease benefited the most from clopidogrel over aspirin.  The relative risk reduction for clopidogrel over aspirin for primary outcome was 23.8% (CI: 8.9 to 36.2), p = 0.0028.  For patients with MI or stroke, the effect of clopidogrel over aspirin was non-significant.

Adverse Effects: Frequency of rash was higher in clopidogrel over aspirin whereas GI bleed was more frequent in aspirin users.

Discussion: For secondary prevention of vascular events, clopidogrel is at least as good as aspirin.  What was surprising in the post-hoc analysis was the apparent benefit of clopidogrel over aspirin in patients with PAD but not in post-MI and post-stroke patients.  I think that this finding is a note of caution that atherosclerosis in all vascular territories is not equivalent, and benefit of a drug in a type of vascular disease does not necessarily generalize.  The trial was generally well-done, but the 21% rate of drug discontinuation in both groups remains a concern and may have masked beneficial effects in intention-to-treat analysis.  In summary, if a patient balks against aspirin for secondary prevention, daily clopidogrel is an equivalent option and may even be better if patient has PAD.

Tuesday, August 7, 2012

Keppra for Subdurals

Motivation: As a medicine intern last year, I often scoffed at the algorithmic recommendation by neurosurgery of Keppra for seven days after every small subdural hemorrhage.  Two nights ago, I self-consciously found myself writing the same recommendation while consulting as neurology for a patient after a fall.  What is the data?

Turns out that there is no high quality randomized trial testing anti-epileptics in acute sub-dural hematomas.  The practice is drawn from literature in traumatic brain injury.

Paper: Chang, B.S. and Lowenstein, D.H.  "Practice Parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury." Neurology (2003); 60: 10-16.

Method: A meta-analysis of prospective placebo controlled trials testing anti-epileptic drugs in traumatic brain injury.  Literature search revealed that data existed only for severe TBI - typically with loss of consciousness or amnesia for 12 to 24 hours, depressed skull fracture, or brain contusion on CT scan.  No constraint was placed on the choice of AED.  Authors separated analysis by prevention of early or late seizures.

Results:
Prevention of Early Seizures: Four randomized trials examined early (less than 7 days) prevention of seizure from TBI.  Three studies used phenytoin and one used carbamazepine.   The pooled RR for seizure on AED compared to placebo was 0.37 (CI: 0.18-0.74).  Of the four studies, one did not find any benefit with AED though that study was hindered by low event rate.  There was no significant increase in frequency of adverse effects in group taking AED.

Prevention of Late Seizures: Five high quality trials tested long-term AED for prevention of seizures.  The treatment duration was 6 months to 2 years (most trials were 1-2 years) with median follow-up of 2 years (five trials) with range of 18 months to 2 years.  Trials used phenytoin, carbamazepine, or valproic acid.  The pooled RR for seizure on AED compared to placebo was 1.05 (CI: 0.82-1.35) demonstrating no benefit - none of the individual studies showed benefit.  Some unblinded studies (not included in pooled analysis) showed benefit.  Adverse effects (particularly rash) was significantly higher in the intervention group than placebo group.

Discussion: In severe TBI, anti-epileptic drugs appear beneficial in preventing seizures in the short term (7 days) but ineffective in the long-term.  This landmark meta-analysis, though, has been commonly extended to justify prescribing anti-epileptics for many minor to mild TBI without changes in consciousness or brain contusions.  Although probably beneficial, the practice is still more opinion based rather than evidence based.    Also, the trials used mostly phenytoin as the anti-epileptic of choice while current practice is more heavily biased towards levetiracetam (Keppra).  While I do not plan to rebel against the seven day course of Keppra for subdurals, there is need for data in this common clinical situation.

Monday, July 16, 2012

New Way for Hypertension

Motivation: Last weekend, I was flipping through an old issue of TIME magazine when I noticed an article with large picture of pink kidneys.  Wondering why TIME magazine would be concerned with urine production, I read a little more and learnt about a "revolutionary" new treatment for hypertension discovered in England in 2010.  The article refers to amazing results published in a trial in Lancet in 2010 from renal sympathetic ablation.  Throughout intern year, we had never seriously considered this therapy.  Why? How good is the data?

Paper: Symplicity HTN-2 Investigators. "Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial" Lancet (2010); 376: 1903-09.

Methods: Multicenter randomized unblinded trial of renal denervation with treatment resistant hypertension, defined as SBP > 160 mmHg (SBP > 150 with DM2) despite compliance on 3 or more anti-hypertensives.  Important exclusion criteria were GFR < 45 and history of MI, unstable angina, or stroke.  Study conducted at Europe, Australia, and New Zealand.  Patients randomized to renal denervation had endovascular catheter directed radioablation through renal artery access.  Primary endpoint was change in average office-based SBP from baseline to 6 months.

Results:
Cohort: In total, 52 patients were randomized to renal denervation while 54 were in the control group.  The two groups were overall similar except for differences in gender (35% female in intervention vs. 50% in control group) and difference in baseline GFR (77 ml/min in intervention vs. 86 in control group). Three patients were lost to follow-up in each group.

Efficacy: In per-protocol analysis, at six-months, renal denervation resulted in mean decrease in BP of 33/11 mmHg compared to no changed in the control group.  The baseline was 178/96 in the intervention group and the same in the control group.  The result is statistically significant, p < 0.0001.  Similar changes were noted in BP measurements at home-based and 24 hour ambulatory measurements.  At least 84% of patients in intervention group had >10 mmHg decrease in SBP at 6 months.

Secondary End Points: There were no differences in serum creatinine, eGFR, and cystatin C between baseline and 6 months in both groups.  There were no differences in composite cardiovascular between the two groups.

Safety: No serious procedure-related or device related complications noted in the six month follow-up.

Discussion: In this preliminary phase trial of renal denervation, the procedure appears remarkably efficacious.  The degree of BP measurement is clearly better than any other current medicinal or lifestyle approach.  Yet, before adopting this intervention, the paper has multiple limitations that need to be clarified.  First, the control and intervention groups were different some important baseline parameters such as gender distribution and GFR.  Second, there were no hard endpoints used in the paper such as MI or long-term cardiovascular outcomes.  It is unclear whether renal denervation has any long-term risks that may outweigh short-term benefits in BP reduction.  Finally, this entire study was funded, designed, and analyzed by Ardian, the maker of the denervation catheter.  The data would gain more integrity if the trial was designed and analyzed independently.  Thus, this therapy is promising but needs a larger follow-up trial before widespread use. 

Sunday, July 8, 2012

Color of the Eyes

Motivation: Part of the checklist on the physical exam is looking at patients' eyes and deciding on paleness. I would love to be able to gauge degree of anemia without Q6 blood draws, but are the eyes a good way to decide on degree of anemia?

For background, while looking at the conjunctiva, pallor is determined by comparing the posterior edge of the palpebra (just where it intersects with the conjunctiva) with the anterior edge of the palpebra bordering the eyelashes.  Normally, the anterior edge is redder than the posterior edge.  In anemia, the anterior and posterior edge are the same color.  Pasted below are pictures of a normal and anemia conjunctival exam:

Normal Conjunctiva

Conjunctival Pallor
 Paper: Sheth, T.N., Choudhry, N.K., Bowes, M. et. al. "The Relation of Conjunctival Pallor to the Presence of Anemia." J. Gen. Intern. Med. (1997); 12: 102-106.





















Methods: 302 medical and surgical inpatients at The Toronto Hospital were prospectively assessed for conjunctival pallor (present/borderline/absent) and compared to the patient's hemoglobin.  The observers (medical students and general internists) were initially trained on 25 patients but were blinded to the hemoglobin levels.  While no primary endpoint was stated, the overall goal was the utility of conjunctival pallor in ruling in or ruling out moderate anemia (hemoglogin < 9 g/dL).

Results:
Cohort: Of the 302 patients examined, 171 were male and 131 were female.  55 had hemoglobin less than 9 g/dL while 247 had higher values.

Conjunctival Pallor:  With hemoglobin cutoff of 9 g/dL, the performance of pallor is as below:
- Sensitivity (pallor present):  14.5%
- Sensitivity (pallor present/borderline): 54.5%
- Specificity (pallor absent): 74.4%.


Discussion: In the final analysis, conjunctival pallor is just not a reliable test for anemia even for trained observers.  A definitely positive test only has sensitivity of about 15%.  Even stretching the boundary to positive or borderline positive only yields a sensitivity of about 54%.  So, anemia cannot be ruled out by conjunctival  pallor.  On the other hand, specificity is somewhat higher though 25% of patients with hemoglobin > 9 g/dL remarkably also had conjunctival pallor.  Thus, if pallor is observed, the patient likely has anemia though even that is not a sure thing (in the study, positive likelihood ratio of 4.49)!  I guess CBC are here to stay.

Saturday, June 30, 2012

Mood Enhancement

Motivation: Recently, one of my friends in psychiatry commented that the blog almost never touches upon psychiatry.  And, that is unfortunately true despite the amount of psychiatric diseases in the medical wards.  So, today, I wanted to examine the question of what happens when the SSRI just does not work after a good six weeks.  Often, I have seen psychiatrists "augment" the treatment with a variety of anti-psychotics.  Is there data behind the practice, and which anti-psychotic is the best one?

Paper: Nelson, J.C. and Papakostas, G.I.  "Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials" Am. J. Psychiatry (2009) 166: 980-991.

Methods: Meta-analysis of double blind randomized trials comparing addition of atypical anti-psychotic versus placebo in patients with non-responsive major depression.  Response was defined as >50% improvement in baseline scores of a depression rating scale (Montgomery-Asberg Depression Scale or Hamilton Depression Scale).

Results:
Trials: In total, 16 trials were analyzed with trial duration ranging from 4-12 weeks (9 trials lasted 8 weeks, 5 lasted 6 weeks, 1 lasted 12 weeks, and 1 lasted 4 weeks).  The agents tested were olanzapine, risperidone, quetiapine, and aripiprazole.  These anti-psychotics were added to anti-depressants which were typically a SSRI or SNRI.

Olanzapine: Overall, meta-analysis of 586 in treatment arm and 414 in control group.  Odds ratio as listed below (higher OR with favorable treatment):
- Response: 1.39 (95% CI: 1.05-1.84), Remission: 1.83 (1.30-2.56)
- Adverse Effect: 3.85 (2.03-7.29)

Risperidone: Analyzed 211 in treatment arm and 175 in control group.  Odds ratios as below:
- Response: 1.83 (1.18-2.82), Remission: 2.63 (1.51-4.57)
- Adverse Effect: 2.84 (0.91-8.91)

Quetiapine:Analyzed 677 in treatment arm and 352 in control group. Odds ratios as below:
- Response: 1.60 (1.24-2.08), Remission: 1.89 (1.41-2.54)
- Adverse Effect: 5.52 (2.71-11.24)

Aripiprazole: Analyzed 540 in treatment arm and 525 in control group. Odds ratios as below:
- Response: 2.07 (1.58-2.72), Remission: 2.09 (1.55-2.81)
- Adverse Effect: 2.68 (1.23-5.81)

Duration of Trial: No effect seen in response to drug based on duration ranging from 4 to 12 weeks.

Discussion:  This meta-analysis both demonstrates the utility of anti-psychotics in treatment resistant depression and the equivalence for the four examined anti-psychotics (despite aripiprazole being the only FDA approved augmentation anti-psychotic).  Interestingly, addition of anti-psychotics also resulted in increased adverse effects pretty uniformly.  The meta-analysis did not describe the most common adverse effects (such as mild or severe or suicidal).  Another limitation of this analysis is that only the acute phase of treatment (4-12 weeks) was examined.  No data about maintenance phase was available although treatment is often extended to the maintenance phase as well.  In summary, when faced with a depressed patient unresponsive to usual first line SSRI/SNRI agents, addition of an accessible anti-psychotic (whether risperidone or aripiprazole) is reasonable though patients should be monitored closely for severity of adverse effects.

Sunday, June 17, 2012

Is this MDS?

Motivation: In the past few months, I have come across multiple patients with chronic unexplained macrocytosis.  I am often tempted to diagnose MDS and request a bone marrow biopsy.  But, is there a better non-invasive scoring system to triage the likelihood of MDS?  Recently, while searching this topic, I came across this paper that estimates a pre-test likelihood of MDS.

Paper: Rauw, J., Wells, R.A., Chesney, A., et. al.  Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.  Leukemia Research (2011) 35: 1335-38.

Methods: Retrospective review of bone marrow biopsies (2006-2008) at an academic hospital in Toronto, Canada.  Inclusion criteria were anemia (hemoglobin <12 g/dL), thrombocytopenia (platelet < 150), leukopenia (WBC < 4), neutropenia, or macrocytosis (MCV > 96).  Patients with known or suspected hemato-lymphoid diseases (such as lymphoma or widespread lymphadenopathy) were excluded.  BM biopsies were classified as MDS, suspected MDS (met most but not all pathological criteria), or not MDS.

Results:
Scoring System: The authors designed a scoring system with four parameters: (1) age >= 65, (2) RDW > 14.5%, (3) MCV > 96, and (4) LDH  > 250.

Bone Marrow Diagnoses: Of the 313 biopsies reviewed, 100 had MDS, 27 had suspected MDS, and 186 did not have MDS.  Among those not having MDS, 34% were normal, 10% had AML, and the rest had other diagnoses.

Sensitivity and Specificity of Confirmed/Suspected MDS Based on Risk Factors:
Risk Factors              Sensitivity              Specificity
>=1 factor                  95%                       18%
>=2 factors                74%                        46%
>=3 factors                39%                        79%
    4 factors                6%                          96%

Discussion: I liked this paper because it provided a risk assessment of MDS based on parameters that are easily and routinely measured.  Having multiple risk factors should lower the threshold for referral to hematology and having a bone marrow biopsy.  As in other retrospective reviews from tertiary medical centers, the numbers in this paper are affected significantly by referral bias.  In the patients with anemia and macrocytosis getting BM biopsy, probably all had B12 and folate checked and had MCV measured when abstaining alcohol.  In the regular inpatient setting, alcoholism as well as B12 deficiency probably accounts for a significant portion of macrocytosis.  For patients without these other more straightforward explanations, stratifying patients for MDS by these risk factors is a quick clinical tool.

Saturday, June 9, 2012

G-CSF for Acute Liver Injury

Motivation: When patients do not respond to steroids for acute alcoholic hepatitis, there is little else you can do - besides watching them wither away.  While observing another such tragedy, I wondered if there is anything else to do.  Most patients with acute alcohol use do not qualify for a liver transplant.  I came across this paper published recently evaluating the remarkable potency of G-CSF for acute on chronic liver injury.

For background, the theory is that G-CSF mobilizes bone marrow derived stem cells (CD 34+), and one hopes that with more stem cells floating around, some will engraft in the liver and lead to regeneration.

Paper: Garg, V., Garg, H., Khan, A. et. al. "Granulocyte Colony-Stimulating Factor Mobilizes CD34+ Cells and Improves Survival of Patients with Acute-on-Chronic Liver Failure" Gastroenterology (2012); 142: 505-512.

Methods: Blinded randomized trial in a hospital in New Delhi, India.   Between December 2008 and August 2010, consecutive patients with acute on chronic liver failure (defined as acute rise in bilirubin, INR, ascites, or encephalopathy in patients with known liver disease) were randomized to placebo or 5 ug/kg G-CSF (12 doses over month).  Exclusion criteria included hepatocellular carcinoma, portal vein thrombosis, multi-organ failure, sepsis, or grade 3 or 4 encephalopathy.  Primary end point was survival at day 60.

Results:
Cohort: In total, 47 patients were randomized with 23 patients to G-CSF and 24 patients to placebo.  Majority of patients were male in each group (3 females in each group).  Mean age was 40 in either arm.  Both groups were balanced in terms of MELD score, grade of varices, CTP score, liver enzyme levels, and encephalopathy.  Most patients had acute alcoholic hepatitis.  The placebo group had more HBV reactivation liver injury.

CD 34 Cells: To verify whether G-CSF actually led to stem cell engrafment, authors compared CD34 cells in liver at baseline and at day 30.  Compared to baseline value of 27.5% CD34 cells in sinusoids (based on cell counting in immunohistochemistry), G-CSF treatment resulted in 45% CD34 cells in sinusoids.  No increase was seen in the placebo group (CD34 cells decreased from 30% to 20%).

Survival: The actuarial probability of survival was 66% with G-CSF versus 26% with placebo (p=0.001).  In total, 7 patients died in G-CSF group versus 17 deaths in placebo arm (majority from progressive multi-organ failure, mostly HRS)

MELD Scores: .Median change in MELD score at days 7, 30, and 60 was -7.4%, -18.23%, and -15.34% in G-CSF group versus +3.33%, +6.25%, and +11.76% in placebo group.

Adverse Effects: G-CSF treatment resulted in three adverse events - one had transient rash, one had herpes zoster, and one had high fevers.  Other patients completed therapy without reported adverse effects.

Discussion: This small randomized trial suggests that G-CSF has significant mortality benefit in acute on chronic liver failure!  In the two month trial period, there were 10 fewer deaths in the G-CSF group suggesting an amazingly large benefit.  There are, of course, a few caveats to this trial.  With the number of recruited patients numbering in the 20s in each group, there is no guarantee that the groups were actually well-balanced.  Also, with two month follow-up, it is unclear whether the effects of G-CSF are persistent or transient.  Clearly, this smaller trial calls for a larger, better designed randomized trial.  In the meantime, if someone with acute on chronic liver failure is perishing on standard therapy, I would strongly consider G-CSF therapy.